FIELD: biotechnologies.
SUBSTANCE: in modified molecule IL-4RA, which inhibits mediated IL-4 and IL-13 activity, amino-acid remains 37, 38 or 104 represent cysteine. Polynucleotide, which codes specified antagonist, in composition of expression vector, is used to transform host cell and produce IL-4RA. Produced molecule IL-4RA is PEGylated and used to eliminate abnormalities that are related to high activity of IL-4 and IL-13.
EFFECT: invention makes it possible to produce antagonist with longer period of half-decay compared to non-modified IL-4RA.
17 cl, 1 dwg, 7 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IL-1beta-BINDING ANTIBODIES AND FRAGMENTS THEREOF | 2006 |
|
RU2518295C2 |
| METHOD OF TREATING AND PREVENTING FIBROSIS BY IL-21/IL-21R ANTAGONISTS | 2006 |
|
RU2419450C2 |
| TEAR LIPOCALIN MUTEINS, BINDING ALPHA IL-4 R | 2011 |
|
RU2569745C2 |
| CLOSTRIDIAL TOXIN NetB | 2008 |
|
RU2474587C2 |
| T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS | 2013 |
|
RU2653761C2 |
| METHOD FOR PREPARING ANTIBODIES HAVING IMPROVED PROPERTIES | 2011 |
|
RU2604811C2 |
| TRANSPOSASE POLYPEPTIDES AND USE THEREOF | 2016 |
|
RU2735700C2 |
| HETERODIMERIC POLIPEPTIDES IL-17 A/F AND POSSIBILITIES OF THEIR THERAPEUTIC APPLICATION | 2007 |
|
RU2440134C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-R[ALPHA] SUSHI DOMAIN | 2012 |
|
RU2644671C2 |
| POLYPEPTIDES OF DIRECTED ACTION | 2006 |
|
RU2393874C2 |
